Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AST-726 is an intranasal spray formulation of hydroxocobalamin acetate, developed as a treatment for vitamin B12 deficiency. It is designed as an isotonic aqueous solution with preservatives and intended to provide a convenient, non-injectable alternative to traditional intramuscular vitamin B12 injections. The drug has demonstrated pharmacokinetic equivalence to the standard injectable form of hydroxocobalamin, supporting its use for both maintenance (once-monthly dosing) and restoration (more frequent dosing) of normal vitamin B12 levels in deficient patients. Its mechanism of action is through direct supplementation and systemic absorption of hydroxocobalamin (vitamin B12), which acts as a cofactor in essential enzymatic reactions involved in DNA synthesis and cellular metabolism[3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AST-726.